{
    "organizations": [],
    "uuid": "000b45429d9414a3aa1cfb954418bd8f65ed5b97",
    "author": "",
    "url": "https://www.reuters.com/article/brief-emergent-biosolutions-and-valneva/brief-emergent-biosolutions-and-valneva-initiate-clinical-study-to-evaluate-vaccine-against-zika-virus-idUSFWN1QG19V",
    "ord_in_thread": 0,
    "title": "BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Emergent Biosolutions Inc:\n* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS\n* EMERGENT BIOSOLUTIONS INC - INITIAL DATA FROM PHASE 1 CLINICAL TRIAL OF VLA1601 ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T00:23:00.000+02:00",
    "crawled": "2018-02-27T00:43:22.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "emergent",
        "biosolutions",
        "inc",
        "emergent",
        "biosolutions",
        "valneva",
        "initiate",
        "phase",
        "clinical",
        "study",
        "evaluate",
        "vaccine",
        "candidate",
        "zika",
        "virus",
        "emergent",
        "biosolutions",
        "inc",
        "initial",
        "data",
        "phase",
        "clinical",
        "trial",
        "vla1601",
        "expected",
        "available",
        "late",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}